BioVie Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023, compared with fiscal year ended June 30, 2022. Although the request metadata says “2022 Q4,” this filing is an annual report for FY2023, not a quarterly filing. BioVie is a clinical-stage biopharmaceutical company with no approved products or product revenue.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $33.3 million | $17.3 million |
| Selling, general and administrative expense | $11.6 million | $9.8 million |
| Total operating expenses / operating loss | $45.1 million | $27.3 million |
| Net loss | $50.3 million | $26.1 million |
| Net cash used in operating activities | $40.3 million | $19.0 million |
- Loss per share was $1.55, compared with $1.06. Revenue-based margins are not meaningful because the company has no revenue.
- At June 30, 2023, cash and cash equivalents were $19.5 million and U.S. Treasury bills were $14.5 million, totaling approximately $33.9 million. Working capital was approximately $19.5 million; stockholders’ equity was $15.3 million and accumulated deficit was $301.2 million.
- Outstanding loan principal was $15 million. The debt is secured by company assets, including intellectual property; $10 million principal was scheduled for payment in FY2024 and $5 million in FY2025. The stated rate is the greater of prime plus 7% or 10.75%; the reported effective rate is 25%. FY2023 interest expense was $4.3 million.
- Financing included approximately $49.5 million net proceeds from sales of 7.54 million shares under the equity offering program and approximately $5.9 million net proceeds from a related-party private placement. Shares issued increased from 24.98 million at June 30, 2022 to 36.45 million at June 30, 2023.
Material changes and operating developments
- Net loss rose by approximately $24.2 million. Higher clinical activity drove most of the increase in R&D expense; other expense also increased, including a roughly $4.7 million year-over-year swing in derivative fair-value effects.
- NE3107 — Alzheimer’s disease: The potentially pivotal Phase 3 study was fully enrolled, with primary completion targeted for calendar Q4 2023. The filing reports exploratory Phase 2 findings, but those results were from a small, open-label, single-arm study and do not establish efficacy.
- NE3107 — Parkinson’s disease: A 45-patient Phase 2 study completed in December 2022. The company reported that safety/drug-interaction and secondary motor-activity objectives were met; further study planning was ongoing.
- BIV201 — refractory ascites: The Phase 2b study stopped before planned full enrollment, after 15 patients received BIV201 plus standard care. The company reported reductions in ascites fluid among treated patients and no unexpected serious adverse events. In June 2023 it requested FDA guidance on definitive testing; written FDA comments were expected in calendar Q3 2023.
Outlook, risks and unusual items
- Management stated that current planned operations could deplete available cash within 12 months of the balance-sheet date. Cash might possibly last longer if planned research and clinical expenditures are delayed. The company expects to seek additional funding through equity, loans or strategic transactions.
- The auditor highlighted substantial doubt about BioVie’s ability to continue as a going concern, citing recurring operating losses and negative operating cash flows. The financial statements include no adjustments for the uncertainty.
- Principal risks include clinical-trial failure or delay, regulatory uncertainty, dependence on third-party manufacturers and research organizations, lack of revenue, need for additional capital, and potential dilution. Outstanding warrants, options and restricted stock units totaled approximately 12.3 million shares at June 30, 2023; the company also disclosed potential milestone issuance of up to 18 million shares under the NeurMedix asset purchase agreement.
- Acuitas, a related party and majority holder, participated in the private placement and was the seller’s assignee in the earlier NE3107 asset acquisition. The filing also reports concentrated ownership and related-party interests.
- The company reported effective disclosure controls and management assessed internal control over financial reporting as effective; the auditor was not engaged to audit internal controls. The auditor identified R&D expense and accruals as a critical audit matter because of estimation and completeness judgments.
Important facts for investors to verify
- Whether NE3107 Phase 3 Alzheimer’s results were completed and disclosed, and how the results compared with the study’s co-primary endpoints.
- FDA feedback and the next definitive-trial plan for BIV201, including the implications of the Phase 2b study ending before full enrollment.
- Cash use, committed clinical spending and financing availability against the going-concern warning and debt repayment schedule.
- Potential dilution from future equity sales, warrants, options, the Acuitas-related milestone shares and any conversion rights.
- The assumptions and reconciliation underlying derivative fair-value expense and R&D accrual estimates, both of which materially affect reported results.